Copyright
©The Author(s) 2015.
World J Hepatol. Aug 18, 2015; 7(17): 2100-2109
Published online Aug 18, 2015. doi: 10.4254/wjh.v7.i17.2100
Published online Aug 18, 2015. doi: 10.4254/wjh.v7.i17.2100
Table 1 Direct-acting antivirals (clinical development status in parenthesis)
| NS3/4A Protease inhibitors | NS5A inhibitors | Polymerase inhibitors | |
| NIs | NNIs | ||
| Telaprevir (approved) | Daclatasvir (approved) | Sofosbuvir (approved) | Dasabuvir (phase 3) |
| Boceprevir (approved) | Ledipasvir (phase 3) | Mericitabine (phase 2) | BMS-791325 (phase 3) |
| Simeprevir (approved) | Ombitasvir (approved) | VX-135 (phase 2) | PPI-383 (phase 1) |
| Asunaprevir (phase 3) | GS-5816 (phase 2) | GS-9669 (phase 2) | |
| Danoprevir (phase 3) | ACH-2928 (phase 1) | TMC647055I (phase 2) | |
| Paritaprevir (approved) | ACH-3102 (phase 2) | VX-222 (phase 2) | |
| Vaniprevir (phase 3) | PPI-668 (phase 2) | ||
| Sovaprevir (phase 2) | PPI-461 (phase 1) | ||
| MK-5172 (phase 3) | GSK2336805 (phase 2) | ||
| ACH-2684 (phase 2) | Samatasvir (phase 2) | ||
| Narlaprevir (phase 2) | MK-8742 (phase 3) | ||
| Vedroprevir (phase 2) | BMS-824393 (phase 2) | ||
- Citation: Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol 2015; 7(17): 2100-2109
- URL: https://www.wjgnet.com/1948-5182/full/v7/i17/2100.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i17.2100